Regulatory status record
Is Alprazolam (Ativan) banned in India?
Last checked 19 September 2026. A few details are still being checked against the original document.
Alprazolam and lorazepam (Ativan) are not banned in India as of 19 Sep 2026; they are Schedule H1 drugs and psychotropic substances under the NDPS Act, which means prescription-only sale with record-keeping, not prohibition.
- Classification
- No ban or recall found in official records
- Decided by
- CDSCO / Ministry of Health and Family Welfare; NDPS Act
- Reference
- No Section 26A notification; Schedule H1 (Drugs and Cosmetics Rules, 2013 amendment); NDPS Act psychotropic schedule
- Latest action
- 1 March 2014
- Last checked
- 19 September 2026details being verified
Alprazolam orally disintegrating tablets in blister packs. Photo: Alprazolam orally disintegrating tablets, blister packs.jpg by Tmeers91 (CC0). Brand names and logos belong to their owners and are used here to identify the product this entry is about. All photo credits.
CDSCO: Drugs banned in India (consumer section)
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Below: Blacklisted's explanationWe organise and explain what the document says. The document above is the authority.
Key facts
- Governing authority
- CDSCO, MoHFW; Narcotics Control Bureau (NDPS)
- Ban notification
- None
- Schedule H1
- Prescription must be retained in a register for 3 years; label carries a red 'Rx' box warning
- NDPS
- Listed psychotropic substances, possession without prescription is an offence
- Common brands
- Alprax, Restyl, Trika (alprazolam); Ativan, Lorel (lorazepam); Nitravet (nitrazepam)
Where the claim comes from
Alprazolam and lorazepam were brought under Schedule H1 in 2014 and are listed psychotropic substances under the NDPS Act, so pharmacies refuse to sell them without a prescription and police seizures of 'Alprax' are regularly reported. Each refusal and each seizure reads as a ban. 'Is Ativan banned in India' also picks up occasional shortage stories.
Alprazolam, sold as Alprax, Restyl and Trika, and lorazepam, sold as Ativan, are benzodiazepines used for anxiety and short-term insomnia. Neither is banned in India, but both are among the most tightly controlled medicines a pharmacy stocks, and the controls are what people experience as a ban.
Two regimes apply. Since 2014 benzodiazepines have been in Schedule H1 of the Drugs and Cosmetics Rules, which requires the pharmacist to see a prescription, record the prescriber's and patient's details in a register kept for three years, and dispense only the quantity prescribed; packs carry a red-bordered warning. Separately, alprazolam and lorazepam are listed as psychotropic substances under the Narcotic Drugs and Psychotropic Substances Act, so possession without a prescription, and sale outside licensed channels, are criminal offences. Police reports of seized "Alprax tablets" are common and are routinely headlined as drug busts.
Neither regime is a Section 26A prohibition. The drugs remain licensed, listed in the National List of Essential Medicines for anxiety and seizures, and available to any patient with a prescription.
Anyone taking a benzodiazepine should not stop abruptly; withdrawal can be dangerous, and a doctor will taper the dose. Anyone buying it online or from informal sellers is committing an offence and, more practically, has no way of knowing what the tablets contain.
What this means for you
You need a valid prescription every time
Pharmacies must record the sale; refusal without a prescription is the law working, not a ban.
Do not stop suddenly
Benzodiazepines need tapering under a doctor's supervision.
Buying online or informally is illegal
Seized 'sleeping pills' are frequently counterfeit; the risk is what is actually in them.
This is a record of official orders, not medical advice. Do not stop a prescribed medicine without asking your doctor or pharmacist.
Entries on the banned drugs list
| Drug / combination | Action | Notification | Date | Status note |
|---|---|---|---|---|
| Mebeverine + Alprazolam | Banned | S.O. 198(E) | 11 January 2019 | One of 80 FDCs prohibited vide S.O. 180(E)-259(E) dated 11.01.2019 (CDSCO letter 22.01.2019). In force per CDSCO list as on 22.11.2021. |
| Paracetamol + Alprazolam | Banned | S.O. 203(E) | 11 January 2019 | One of 80 FDCs prohibited vide S.O. 180(E)-259(E) dated 11.01.2019 (CDSCO letter 22.01.2019). In force per CDSCO list as on 22.11.2021. |
Batches declared Not of Standard Quality
Batches of products containing Alprazolam flagged in CDSCO monthly alerts. An NSQ result concerns one batch, not the molecule or the brand.
| Product | Batch | Manufacturer | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|---|
| Alprazolam Tablets IP 0.5mg | TA25315Mfg 2025-03 · Exp 2028-02 | SAINTLIFE PHARMACEUTICALS LTDUttarakhand | The sample does not conform to the IP with respect to Dissolution.Dissolution | DTL JaipurState lab | Jul 2026 |
| Alprazolam Tablets IP 0.50 mg | AT25417Mfg 2025-10 · Exp 2028-09 | Aarpik Pharmaceuticals Pvt. Ltd. C1/306/5Kerala | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| Lorazepam Tablets IP 1mg | NTE0461Mfg 2024-07 · Exp 2026-06 | Digital VisionHimachal Pradesh | Assay and DissolutionAssay | SDT&RL, BhubaneswarState lab | Jun 2026 |
| Lorazepam Tablets I.P. 2 mg | T240628Mfg 2024-06 · Exp 2027-05 | Micron Pharmaceuticals | Dissolution.Dissolution | RDTL ErnakulamState lab | May 2026 |
| Lorazepam Tablets IP 1mg, | 5071TNIMfg 2025-04 · Exp 2028-03 | Windlas Biotech Limited (Plant-2)Uttarakhand | The particular sample fails the tests Dissolution and Assay.Assay | RDTL ErnakulamState lab | Jan 2026 |
| Lorazepam Tablets I.P. 1 mg | OM-10584Mfg 2024-07 · Exp 2027-06 | D.D. Pharmaceuticals Pvt. LtdRajasthan | The sample does not conform to claim as per I.P. 2022 with respect to the test for Dissolution and Assay of Lorazepam.Assay | RDTL,GuwahatiCDSCO lab | Jan 2026 |
| Lorazepam Injection IP 2 mg/ml, 2 ml WELOR | WALV24001AMfg 2024-10 · Exp 2026-03 | Welcure Remedies Nahan RoadHimachal Pradesh | The sample does not conform to I.P. with respect to test for Particulate matter, Assay and is also not of standard quality for The reason stated under Description.Assay | CDL, KolkataCDSCO lab | Dec 2025 |
| Alprazolam Tablets IP (0.5 mg) | 3332Mfg 2024-05 · Exp 2027-04 | Reliance Formulation Pvt. Ltd. 7/2-AGujarat | The sample does not conform to claim as per IP 2022 in respect to the Test of DissolutionDissolution | RDTL,ChandigarhCDSCO lab | Nov 2025 |
| Lorazepam Tablets | LALO24014Mfg 2024-11 · Exp 2027-10 | Chimak Health CareHimachal Pradesh | Dissolution test and Assay for LorazepamAssay | KarnatakaState lab | Aug 2025 |
| Lorazepam Tablets IP (LORAT-1) | NR/240715Mfg 2024-07 · Exp 2026-12 | SBS BiotechHimachal Pradesh | The Dissolution of Lorazepam does not complies within the prescribed limit of not less than Q value i.e 60% of labelled claim and 80% of labelled claim after 30 min. (45.09%) and after 60 min.(71.34%) respectively as stated in I.P 2022.Dissolution | State Drugs Laboratory, PunjabState lab | Jul 2025 |
| LORAZEPAM TABLETS IP 2mg (ARKAPAM-2) | ST-26091Mfg 2025-01 · Exp 2027-06 | Sunvij Drugs Private Limited | Assay (for Lorazepam)Assay | DTL, PuducherryState lab | Jul 2025 |
| Lorazepam Tablets IP 2 mg (Proline-2) | 05P23T03Mfg 2023-03 · Exp 2027-02 | Shine Pharmaceuticals LimitedGujarat | Assay for LorazepamAssay | State Lab KarnatakaState lab | Jun 2025 |
| Lorazepam Tablets I.P (1 mg) | 3305Mfg 2024-04 · Exp 2028-03 | Reliance Formulation Pvt. Ltd | Assay for Lorazepam? and ?Dissolution TestAssay | State Lab KarnatakaState lab | Jun 2025 |
| Alprazolam Tablets I.P. 0.50 mg (Calmpik-05) | AT24266Mfg 2024-07 · Exp 2027-06 | Aarpik Pharmaceuticals Pvt.LtdKerala | DissolutionDissolution | RDTL, GuwahatiCDSCO lab | Mar 2025 |
| Lorazepam Tablets IP 1 mg (PROLINE - 1) | 06P23T03Mfg 2023-08 · Exp 2027-04 | Shine Pharmaceuticals LimitedGujarat | AssayAssay | CDTL MumbaiCDSCO lab | Jan 2025 |
Official sources and primary records
- Regulator
- Regulator